Clinical Trials Search

Official Title: A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em

Study Purpose: To determine if cabozantinib or the combination of dabrafenib and trametinib works better to prolong the time until the tumor grows or spreads after initial treatment stops working.

Status: Recruiting

Official Title: Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR

Study Purpose: To evaluate the best objective response rate of AZD9291 (osimertinib) among patients with EGFR exon 20 insertions.

Status: Recruiting

Official Title: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05 / OptimICE-RD)

Status: Recruiting

Official Title: A Phase 3, Randomized, Open-label, Multicenter Study of MK-2870 Maintenance with or without Bevacizumab versus Standard of Care in Participants With Newly-Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy

Study Purpose: To test the safety of sac-TMT when given alone or with bevacizumab; to see how well sac-TMT +/- bevacizumab works compared to standard of care treatment; and to compare the quality of life of participants receiving the study treatment vs. standard of care treatment

Status: Recruiting

Official Title: A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as First-line Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)

Study Purpose: To test the safety and efficacy of sacituzumab tirumotecan (sac-TMT) in people with cervical cancer that has returned or spread to other parts of the body during or after receiving treatment, or is not likely to be cured with surgery and/or radiation

Status: Recruiting

Official Title: A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1)

Study Purpose: To understand how well INCB123667 works, how safe it is, and how well it is tolerated in people with platinum-resistant ovarian cancer whose tumors have high levels of cyclin E1.

Status: Recruiting

Official Title: A Randomized, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

Study Purpose: To find out about the safety and efficacy (how well a drug works) of AZD5335 for the treatment of platinum-resistant ovarian cancer by comparing AZD5335 to standard of care therapies.

Status: Recruiting

Official Title: A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer

Study Purpose: To test the safety, efficacy, and effect on quality of life of sac-TMT when given alone, with bevacizumab, or compared to no maintenance treatment.

Status: Recruiting

Official Title: Blood and Tissue Procurement Protocol for Product Development and Research

Study Purpose: To collect cancerous tissue/fluid and blood samples to store and use for research purposes.

Status: Recruiting

Official Title: Clinical Trial Title    A Study to Evaluate the Safety and Effectiveness of the InnaVasc Arteriovenous Graft for Hemodialysis Access in Patients with End-Stage Renal Disease (InnaVasc)

Study Purpose: This clinical trial is a prospective, multi-center, single-arm study designed to assess the safety and effectiveness of the IG device in subjects with ESRD who require hemodialysis.

Status: Recruiting